Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + enzalutamide
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Atezolizumab + enzalutamide is a combination regimen consisting of **atezolizumab**, a humanized monoclonal antibody inhibitor of programmed death-ligand 1 (PD-L1), and **enzalutamide**, an oral androgen receptor inhibitor. This combination was investigated primarily in metastatic castration-resistant prostate cancer (mCRPC), based on the hypothesis that enzalutamide might enhance interferon-gamma signaling and thus sensitize tumor cells to immune-mediated cytotoxicity induced by PD-L1/PD-1 inhibition. The combination was studied in the phase 3 IMbassador250 trial in patients with mCRPC after failure of androgen synthesis inhibitors and a taxane regimen. The trial found no added efficacy with this combination versus enzalutamide alone in unselected patients.
- Other names
- atezolizumab plus enzalutamide
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)AR (Adrenergic receptors)
Beyond the preview
Go deeper on atezolizumab + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + enzalutamide.